Premium
A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: Phase II)
Author(s) -
Carrascosa JM,
Pujol R,
Daudén E,
HernanzHermosa JM,
Bordas X,
Smandia JA,
Ferrándiz C
Publication year - 2006
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.2006.01659.x
Subject(s) - medicine , psoriasis , observational study , medical prescription , indirect costs , prospective cohort study , direct cost , demographics , medical costs , health care , emergency medicine , dermatology , demography , nursing , accounting , sociology , economics , business , economic growth
Objective To estimate the direct and indirect costs related to psoriasis in Spain. Methods We performed a 12‐month, multicentre, prospective longitudinal and observational study. Overall expense of care was assessed as the sum of direct and indirect costs. Results A total of 797 patients with varying demographics and different degrees of severity of psoriasis were included in the study. The mean total cost of psoriasis, including direct and indirect items, was 1079€ per patient and year. The major sources of expenditure were prescription drugs (46.6%), followed by medical activities (34.5%). Mean costs in patients with moderate and severe psoriasis were approximately 1.5 and 2.5 times higher than in those with mild psoriasis, respectively. Conclusions In Spain, psoriasis is associated with substantial costs both to the National Health System and to the patients.